The B-cell depleting therapy is indicated for adults with generalized myasthenia gravis and anti-acetylcholine receptor or ...

Please provide your email address to receive an email when new articles are posted on . Researchers produced an algorithm to standardize virtual myasthenia gravis assessments. More efforts are needed ...

Jonathan Strober, MD, discusses promising results from the VIBRANCE-MG trial, highlighting nipocalimab's safety and efficacy for pediatric myasthenia gravis.

Key barriers include misdiagnosis, insufficient gMG knowledge among healthcare providers, and limited access to specialists, ...

The FDA in April 2025 approved nipocalimab (Imaavy) as a treatment for people living with generalized myasthenia gravis (gMG). Specifically, nipocalimab is for people with gMG who are 12 and older and ...

Myasthenia gravis (MG) has been treatable for nearly 100 years. In 1934, the Scottish doctor Mary Broadfoot Walker, MD, discovered that the drug physostigmine improved muscle function in people with ...

Heightened focus on delays in diagnosing generalized myasthenia gravis (gMG) follows the promise of better results for some patients with newer treatments that include complement inhibitors and ...

Myasthenia gravis, or MG, is "a chronic autoimmune neuromuscular disorder that causes muscle weakness and fatigue," says Hesterlee. It occurs "when a person’s immune system is essentially attacking ...

Vyvgart, an FcRn inhibitor already approved for generalized myasthenia gravis, is also being tested in myositis, Sjögren’s ...